ACM
BIO icon

Anfield Capital Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Anfield Capital Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-4
Closed -$3K – 102
2021
Q3 		$3K Buy
+4
New +$3K ﹤0.01% 99

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Anfield Capital Management's BIO Position: Q4 2021 in Review

Anfield Capital Management sold out of Bio-Rad Laboratories Class A (BIO) in Q4 2021, closing a stake of 4 shares — an estimated $3K sold.

Anfield Capital Management first reported a position in BIO in Q3 2021 and held it in 1 quarter. The position peaked at $3K in Q3 2021. 533 funds tracked by Wall St. Rank hold BIO as of Q4 2021.

  • Anfield Capital Management reported no remaining Bio-Rad Laboratories Class A position as of Q4 2021 after selling out during the quarter.
  • Anfield Capital Management sold 4 Bio-Rad Laboratories Class A shares in Q4 2021, an estimated $3K.
  • Anfield Capital Management first reported a position in Bio-Rad Laboratories Class A in Q3 2021 and held it in 1 quarter.
  • Anfield Capital Management's Bio-Rad Laboratories Class A position peaked at $3K in Q3 2021.
  • 533 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q4 2021.

Based on Anfield Capital Management's 13F filing for Q4 2021, filed 3 Feb 2022.